Cyllene Therapeutics raises €33 million in Series C financing led by GordonMD Global Investments and M Ventures for EG110A development and pipeline expansion.
Amount Raised
€33 Million
Round Type
Series C
ParisBiotechnologyHealth CareTherapeuticsInvestors
Description
Cyllene Therapeutics, formerly EG 427, has closed a €33 million Series C financing led by GordonMD Global Investments and M Ventures. This funding will support the clinical development of EG110A and expand its HERMES platform. The company recently rebranded, reflecting its growth as a late-stage biotech. CEO Philippe Chambon stated this financing is key for advancing their targeted DNA medicines.
Quick answer
Cyllene Therapeutics raised €33 Million in a Series C round, dated July 7, 2026. Investors: Andera Partners Sas, Bpifrance Investissement, Lamond Ventures, M Ventures and GordonMD Global Investments. Cyllene Therapeutics is based in Paris, Ile-de-France, France.
- How much did Cyllene Therapeutics raise?
- Cyllene Therapeutics raised €33 Million in a Series C round on July 7, 2026.
- Who invested in Cyllene Therapeutics?
- Andera Partners Sas, Bpifrance Investissement, Lamond Ventures, M Ventures and GordonMD Global Investments are named as investors in this round.
- What does Cyllene Therapeutics do?
- Cyllene Therapeutics, formerly known as EG 427, is a clinical-stage biotechnology company focused on the development of precision genetic medicines for neurological diseases.
- Where is Cyllene Therapeutics based and how big is it?
- Cyllene Therapeutics is based in Paris, Ile-de-France, France.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Cyllene Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Amylyx Pharmaceuticals raised $500M (Post-IPO Equity) on August 20, 2026.
- Kynexis raised $46M (Series A) on August 19, 2026.
- Abcuro raised $66M (Series D) on August 18, 2026.
- bioAffinity Technologies raised $4M (Post-IPO Equity) on August 14, 2026.
- Apollomics raised $10M on August 14, 2026.
- Khartis Therapeutics raised $50M (Series B) on August 13, 2026.
Who to call at Cyllene Therapeutics, and when
A new round usually means Cyllene Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Cyllene Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Cyllene Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Cyllene Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Cyllene Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Cyllene Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.